Moreover, by an immunofluorescence-based approach, it has been possible to monitor the subcellular localization of RANBP1 in ovarian cancer cells following the selective inhibitor S109 administration, thus strengthening the hypothesis of CRM1 as a possible target in cancer therapy, for its ability to block cell proliferation in ovarian cancer as well as colorectal cancer [66]. Here, XPO1 is linked to ovarian cancer.